The Expression And Signifcance Of KiSS-1, GPR54 And MMP-9 In Endometrial Carcinoma

The aim of this study was to detect the expression of KiSS-1 peptide metas-tin, MMP-9 protein in endometrial carcinoma tissues and the expression of KiSS-1, GPR54, MMP-9 mRNA in endometrial carcinoma freezing tissues to probe the clinical significance of them in endometrial carcinoma and the correlation of KiSS-1 and MMP-9.MethodsThe expression, correlation and their clinical significance of KiSS-1 peptide metastin and MMP-9 protein in 50 patients with endometrial carcinoma, 13 patients with EIN and 18 patients with normal endometrium were detected by im-munohistochemistry of streptavidin-peroxidase (SP) method. Meanwhile, the expression, correlation and their clinical significance of KiSS-1, GPR54 and MMP-9 mRNA in 32 patients with endometrial carcinoma, 10 patients with EIN and 12 patients with normal endometrium were detected by reverse transcriptase polymerase chain reaction (RT-PCR) method.ResultsThe positivity of KiSS-1 peptide metastin in patients with endometrial carcinoma (48% ) was lower than in patients with EIN (92. 3% ) and normal endometrium (83. 3% ) . The expression of KiSS-1 peptide metastin in patients with endometrial carcinoma correlated with their clinical stage, histology grade, myo-metrial invasion and lymph node metastasis( P <0.05). The positivity of MMP-9 in patients with endometrial carcinoma (58% ) and EIN (76.9% ) were higher than in patients with normal endometrium (27.8% ). The positivity of MMP-9 in patients with endometrial carcinoma correlated with their clinical stage and myometrial invasion( P <0.05). The expression of KiSS-1 peptide metastin correlated negatively with the expression of MMP-9 protein in patients with endometrial carcinoma. The positivity and relative contents of KiSS-1 mRNA in patients with endometrial carcinoma (37.5% ,46. 83 +2.66) were all lower than in patients with EIN (80% ,56.75 + 1.94) and normal endometrium(83.3% ,56.79 + 1.62). The positivity of KiSS-1 mRNA in patients with endometrial carcinoma correlated with their clinical stage, myometrial invasion and lymph node metastasis ( P <0. 05) . The positivity of GPR54 mRNA in patients with endometrial carcinoma (78.1% ) was higher than in patients with EIN (70. 0% ) and normal endometrium (27. 8% ) , there was no difference among them ( P >0.05 ). But the relative content of GPR54 mRNA in patients with endometrial carcinoma was higher than in patients with normal endometrium. The positivity and relative contents of GPR54 mRNA in patients with endometrial carcinoma did not correlate with their clinical stage, histology grade, myometrial invasion and lymph node metastasis (P >0. 05). There was no difference in the positivity of MMP-9 in patients with endometrial carcinoma (46.9% ) , EIN (40% ) and normal endometrium (25% ), but the relative contents of MMP-9 mRNA in patients with endometrial carcinoma was higher than in patients with normal endometrium. The positivity of MMP-9 mRNA in patients with endometrial carcinoma correlated with their clinical stage and lymph node metastasis (P <0.05 ). The expression of KiSS-1 mRNA correlated negatively with the expression of MMP-9 mRNA in patients with endometrial carcinoma.DiscussionKiSS-1 was a novel human cancer metastasis-suppressor gene, which was found in melanoma cell line by Lee with subtractive hybridization technique in 1996. KiSS-1 gene is mapped to chromosome 1q32 ~q41. KiSS-1 gene encodes a protein of 145 amino acid long, which can be cleavaged to 54 amnio acids, 14amnio acids and 13 amnio acids peptides. Many interactions involving SH-3 domain have been directly or indirectly associated with various steps in the metastasis cascade. KiSS-1 protein has a proline rich region with homology to SH3 binding domain that could predict a mechanism for cancer metastasis supression. KiSS-1 encodes a COOH-terminally amidated peptide with 54 amino-acid residues , which is called metastin and this peptide is a natural ligand of a novel human orphan G-protein coupled protein receptor GPR54 or AXOR12. Activation of the receptor by KiSS-1 p...